Compare TCPC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | CADL |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.2M | 357.4M |
| IPO Year | 2006 | 2021 |
| Metric | TCPC | CADL |
|---|---|---|
| Price | $4.37 | $7.18 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $3.50 | ★ $19.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 17.55% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.43 | $4.34 |
| 52 Week High | $8.05 | $7.24 |
| Indicator | TCPC | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 66.86 | 81.28 |
| Support Level | $3.43 | $5.25 |
| Resistance Level | $5.99 | $7.24 |
| Average True Range (ATR) | 0.16 | 0.35 |
| MACD | 0.11 | 0.22 |
| Stochastic Oscillator | 89.62 | 85.02 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.